Golimumab for the treatment of ulcerative colitis

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time. Based Systematic Review Gastroenterology. 2012;1421:46–54 e42. quiz e30.
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-65 e1-3.
   Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95. quiz e14-5.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. .
   PubMed Web of Science ®Google Scholar
• Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127–142.
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428–439.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pharmacokinetic properties. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000992/WC500052368.pdf
   Google Scholar
• European Medicines Agency. Pharmacological properties. Immunogenicity. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000992/WC500052368.pdf
   Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Marano CW, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42(5):504–514.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Reinisch W, Gibson P, et al. Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome-post hoc analyses from the PURSUIT programme. Abstract DOP048. Available from: https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2016/item/dop048-delayed-response-to-golimumab-therapy-uc-patient-characteristics-and-long-term-clinical-outcomex2014post-hoc-analyses-from-the-pursuit-programme.html
   Google Scholar
• Gibson PR, Feagan BG, Sandborn WJ, et al. Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 year. Clin Transl Gastroenterol. 2016;7:e168.
   PubMed Web of Science ®Google Scholar
• Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol. 2014;28(6):325–329.
   PubMed Web of Science ®Google Scholar
• Singh S, Garg SK, Wang Z, et al. Letter: comparative efficacy of biological therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2014;39(12):1432–1433.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–671.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–711.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11(1):35–46.
   PubMed Web of Science ®Google Scholar
• Detrez I, Dreesen E, Van Stappen T, et al. Variability in golimumab exposure: a ‘Real-Life’ observational study in active ulcerative colitis. J Crohns Colitis. 2016;10(5):575–581.
   PubMed Web of Science ®Google Scholar
• Drabik A, Sturm A, Blomacher M, et al. Early monitoring of response (MORE) to golimumab therapy based on fecal calprotectin and trough serum levels in patients with ulcerative colitis: a multicenter prospective study. JMIR Res Protoc. 2016;5(2):e124.
   PubMed Web of Science ®Google Scholar
• Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43(12):2120–2130.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR–2):1–24.
   PubMedGoogle Scholar
• Androulakis I, Zavos C, Christopoulos P, et al. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol. 2015;21(47):13205–13211.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727–739.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci. 2016;12(5):1097–1109.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015;9(5):693–700.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–781.
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964–975.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276–282.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Siegel CA, Colombel JF, et al. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63(12):1843–1853.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–226.
   PubMed Web of Science ®Google Scholar